All In Biotech

Drug Trial Radar · NCT06255886

Treatment of Gastroesophageal Reflux Disease in Infants

Treatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Oct 27, 2025

Primary completion

Dec 26, 2026

Study completion Dec 26, 2026

Sponsor

Lead sponsor
Odense University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastroesophageal reflux disease in infants is not fully understood. Infants are prescribed medical treatments that may not be effective or that contribute to adverse side effects and lead to concerns and expenses for the parents and healthcare system. Current guidelines recommend cow-milk-protein free diet as a first-line treatment, but these recommendations are based on weak evidence. This study investigate the efficacy of a cow-milk-protein free diet compared to treatment with a proton pump inhibitor (omeprazole)

Conditions

  • Gastroesophageal Reflux
  • Infant, Newborn, Diseases

Interventions

  • Protein pump inhibitor.Drug

    1 mg/kg /day

  • Mother or infant dietBehavioral

    Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed

  • PlaceboDrug

    Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in reflux episodes in the fourth week of active treatment, compared to placeboTime frame: Baseline and daily in 4 weeks.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Paediatric Department, Hospital of Southern Jutland

    Aabenraa, Region Syddanmark, Denmark · Recruiting

  • Børnelægecentret v/Kasper Dalby

    Odense, Region Syddanmark, Denmark · Not yet recruiting

  • H.C Andersen Childrens' Hospital

    Odense, Region Syddanmark, Denmark · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.